4934-99-0

Basic information

• Product Name: Methyl 3-hydroxycyclobuta...
• Synonyms: Methyl 3-hydroxycyclobuta...;Cyclobutanecarboxylic acid, 3-hydroxy-, methyl ester;methyl 3-hydroxycyclobutanecarboxylate;3-Hydroxycyclobutanecarboxylic acid methyl ester;Methylester of 3-hydroxycyclobutane-1-carboxylic acid;methyl 3-hydroxycyclobutane-1-carboxylate
• CAS NO: 4934-99-0
• Molecular Formula: C₆H₁₀O₃
• Molecular Weight: 130.1418
• Mol File: 4934-99-0.mol

Chemical Properties

• Boiling Point: 190℃
• Flash Point: 76℃
• Appearance: /
• Density: 1.232
• Storage Temp.: 2-8°C
• PKA: 14.73±0.40(Predicted)
• CAS DataBase Reference: Methyl 3-hydroxycyclobuta...(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-hydroxycyclobuta...(4934-99-0)
• EPA Substance Registry System: Methyl 3-hydroxycyclobuta...(4934-99-0)

Safety Data

• Hazardous Substances Data: 4934-99-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Methyl 3-hydroxycyclobutane-1-carboxylate is used as a research compound for its distinctive properties, allowing scientists to explore its potential applications and interactions in chemical reactions.
Used in Manufacturing Processes:
This organic compound is employed as an intermediate in the synthesis of various products, contributing to the development of new materials and compounds in the manufacturing industry.
Used in Laboratory Experiments:
Methyl 3-hydroxycyclobutane-1-carboxylate is used as a reactant in various chemical reactions, providing insights into its reactivity and potential applications in different fields.

Upstream product

• 84182-46-7 3-(benzyloxy)cyclobutane-1,1-dicarboxylic acid 
• 54166-15-3 diethyl 3-(benzyloxy)cyclobutane-1,1-dicarboxylate 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 695-95-4 methyl 3-oxocyclobutanecarboxylate 
• 4934-97-8 diisoamyl 3-benzyloxycyclobutane-1,1-dicarboxylate 
• 4958-02-5 3-(benzyloxy)cyclobutane-1-carboxylic acid 
• 4934-98-9 methylester of 3-benzyloxycyclobutane-1-carboxylic acid 

Downstream Products

• 4958-03-6 <3-Methoxycarbonyl-cyclobutyl>-benzolsulfonat 
• 112623-19-5 3-(hydroxymethyl)cyclobutanol 
• 344338-13-2 methylester of 3-p-toluenesulfonyloxycyclobutane-1-carboxylic acid 
• 4935-01-7 methyl bicyclo<1.1.0>butane-1-carboxylate 
• 5071-67-0 Bicyclo<1.1.0>butan-1-methyl-(4-nitro-benzoat) 
• 1073477-11-8 [3-[tert-butyl(diphenyl)silyl]oxycyclobutyl]methanol 
• 4934-98-9 methylester of 3-benzyloxycyclobutane-1-carboxylic acid 
• 84182-50-3 methyl (E)-3-benzyloxycyclobutane-1-carboxylate 
• 1034044-68-2 3-{3-[6-{[4-(Trifluoromethoxy)phenyl]sulfonyl}-2-(trifluoromethyl)-6,11-dihydro-5H-pyrido[2,3-b][1,5]benzodiazepin-7-yl]-1,2,4-oxadiazol-5-yl}cyclobutanol 
• 1547065-03-1 3-fluorocyclobutanecarboxylic acid methyl ester 
• 194788-10-8 cis-3-hydroxycyclobutylcarboxylic acid 

Relevant articles and documents

Bicyclobutane carboxylic amide as a cysteine-directed strained electrophile for selective targeting of proteins

Expanding the repertoire of electrophiles with unique reactivity features would facilitate the development of covalent inhibitors with desirable reactivity profiles. We herein introduce bicyclo[1.1.0]butane (BCB) carboxylic amide as a new class of thiol-reactive electrophiles for selective and irreversible inhibition of targeted proteins. We first streamlined the synthetic routes to generate a variety of BCB amides. The strain-driven nucleophilic addition to BCB amides proceeded chemoselectively with cysteine thiols under neutral aqueous conditions, the rate of which was significantly slower than that of acrylamide. This reactivity profile of BCB amide was successfully exploited to develop covalent ligands targeting Bruton's tyrosine kinase (BTK). By tuning BCB amide reactivity and optimizing its disposition on the ligand, we obtained a selective covalent inhibitor of BTK. The in-gel activitybased protein profiling and mass spectrometry-based chemical proteomics revealed that the selected BCB amide had a higher target selectivity for BTK in human cells than did a Michael acceptor probe. Further chemical proteomic study revealed that BTK probes bearing different classes of electrophiles exhibited distinct off-target profiles. This result suggests that incorporation of BCB amide as a cysteine-directed electrophile could expand the capability to develop covalent inhibitors with the desired proteome reactivity profile.

Quinazolinone Compound and Application Thereof

The present invention relates to a series of quinazolinone compounds and applications thereof as PI3Kα inhibitors. In particular, the present invention relates to a compound shown in formula (I) and a tautomer or pharmaceutically acceptable salt thereof.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

NOVEL HYDRAZIDE CONTAINING COMPOUNDS AS BTK INHIBITORS

The present invention relates to novel hydrazide containing compounds as Bruton tyrosine kinase inhibitors, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders involving mediation of Bruton tyrosine kinase in humans.

Synthesis method of cis-3-hydroxycyclobutylcarboxylic acid

The invention belongs to the field of organic synthesis, and discloses a synthesis method of cis-3-hydroxycyclobutylcarboxylic acid. The synthesis method comprises the following steps: performing efficient stereoselective reduction on 3-carbonyl-cyclobutanecarboxylate (C1-C6 alkyl ester) into single cis-3-hydroxy-cyclobutanecarboxylate by using a proper reducing agent, and performing a hydrolysisreaction to finally obtain the single cis-3-hydroxy-cyclobutanecarboxylic acid. By the synthesis method, raw materials are easy to obtain, the reaction condition is mild, the stereoselectivity is good, and the yield is relatively high; in addition, post-treatment and purification are easy to operate, and the synthesis method is suitable for industrial scale-up production.

Synthesis of Electron-Deficient Heteroaromatic 1,3-Substituted Cyclobutyls via Zinc Insertion/Negishi Coupling Sequence under Batch and Automated Flow Conditions

Synthesis of 1,3-substituted cyclobutyls enabled by zinc insertion into functionalized iodocyclobutyl derivatives followed by Negishi coupling with halo-heteroaromatics is reported. Two distinct sets of conditions were developed; the first involved a two-step batch protocol using activated Rieke zinc, and the second involved a multistep continuous flow process. Both methods showed complementarity and allowed for rapid access to these medicinally relevant motifs, the possibility of scaling up, and automation for library synthesis.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compound and composition thereof, and uses of substituted heteroaryl compound and composition thereof

The present invention provides a substituted heteroaryl compound and a composition thereof, and uses of the substituted heteroaryl compound and the composition, wherein the compound is a compound represented by a formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound represented by the formula (I). The present invention further provides a pharmaceutical composition containing the compound, wherein the pharmaceutical composition can regulate activity of protein kinases, particularly Aurora kinases and JAK kinases, and can be used for prevention, treatment, therapy and alleviation of protein kinases, particularly Aurora kinases and JAK kinase activity mediated diseases or disorders.

Containing cyclobutane substituent of pyrazines, its composition and use thereof

The invention relates to a cyclobutane substituent group-containing pyrazine compound and application thereof as a drug, and particularly relates to application of the cyclobutane substituent group-containing pyrazine compound in preparing the drug for preventing and treating various influenza viruses. Especially, the invention relates to a compound as shown in a general formula (I) or a stereomer, a geometrical isomer, a tautomer, a nitrogen oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and various variables are defined in the specification. The invention also relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug, and particularly relates to application of the compound as shown in the general formula (I) or the stereomer, geometrical isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof as the drug for preventing and treating the influenza viruses.

Substituted purine neuraminidase inhibitor and method of use thereof, and use thereof

The invention provides novel substituted purine compounds or stereoisomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof. The substituted purine compounds are used for inhibiting neuraminidase. The invention also provides a drug composition comprising the compounds, and a method for preventing or treating virus infectious diseases by using the compounds or the drug composition.